Myocarditis, when the heart muscle gets inflamed, can make it harder for the heart to pump blood possibly causing chest pain, ...

FRIDAY, June 27, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has added new warnings to the Pfizer and ...

(Reuters) -Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare ...

With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi (marstacimab ...

The Food and Drug Administration is now requiring two common COVID-19 vaccines to update their warning labels to include ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

The Food and Drug Administration said Wednesday it was expanded existing warnings on the two leading COVID vaccines about a ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...